Cargando…
Quadrivalent Formulation of Intranasal Influenza Vaccine M2SR (M2-Deficient Single Replication) Protects against Drifted Influenza A and B Virus Challenge
Current influenza vaccines demonstrate low vaccine efficacy, especially when the predominantly circulating strain and vaccine are mismatched. The novel influenza vaccine platform M2- or BM2-deficient single replication (M2SR and BM2SR) has been shown to safely induce strong systemic and mucosal anti...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142185/ https://www.ncbi.nlm.nih.gov/pubmed/37112710 http://dx.doi.org/10.3390/vaccines11040798 |
_version_ | 1785033553728241664 |
---|---|
author | Hill-Batorski, Lindsay Hatta, Yasuko Moser, Michael J. Sarawar, Sally Neumann, Gabriele Kawaoka, Yoshihiro Bilsel, Pamuk |
author_facet | Hill-Batorski, Lindsay Hatta, Yasuko Moser, Michael J. Sarawar, Sally Neumann, Gabriele Kawaoka, Yoshihiro Bilsel, Pamuk |
author_sort | Hill-Batorski, Lindsay |
collection | PubMed |
description | Current influenza vaccines demonstrate low vaccine efficacy, especially when the predominantly circulating strain and vaccine are mismatched. The novel influenza vaccine platform M2- or BM2-deficient single replication (M2SR and BM2SR) has been shown to safely induce strong systemic and mucosal antibody responses and provide protection against significantly drifted influenza strains. In this study, we demonstrate that both monovalent and quadrivalent (Quad) formulations of M2SR are non-pathogenic in mouse and ferret models, eliciting robust neutralizing and non-neutralizing serum antibody responses to all strains within the formulation. Following challenge with wildtype influenza strains, vaccinated mice and ferrets demonstrated reduced weight loss, decreased viral replication in the upper and lower airways, and enhanced survival as compared to mock control groups. Mice vaccinated with H1N1 M2SR were completely protected from heterosubtypic H3N2 challenge, and BM2SR vaccines provided sterilizing immunity to mice challenged with a cross-lineage influenza B virus. Heterosubtypic cross-protection was also seen in the ferret model, with M2SR vaccinated animals exhibiting decreased viral titers in nasal washes and lungs following the challenge. BM2SR-vaccinated ferrets elicited robust neutralizing antibodies toward significantly drifted past and future influenza B strains. Mice and ferrets that received quadrivalent M2SR were able to mount immune responses equivalent to those seen with each of the four monovalent vaccines, demonstrating the absence of strain interference in the commercially relevant quadrivalent formulation. |
format | Online Article Text |
id | pubmed-10142185 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101421852023-04-29 Quadrivalent Formulation of Intranasal Influenza Vaccine M2SR (M2-Deficient Single Replication) Protects against Drifted Influenza A and B Virus Challenge Hill-Batorski, Lindsay Hatta, Yasuko Moser, Michael J. Sarawar, Sally Neumann, Gabriele Kawaoka, Yoshihiro Bilsel, Pamuk Vaccines (Basel) Article Current influenza vaccines demonstrate low vaccine efficacy, especially when the predominantly circulating strain and vaccine are mismatched. The novel influenza vaccine platform M2- or BM2-deficient single replication (M2SR and BM2SR) has been shown to safely induce strong systemic and mucosal antibody responses and provide protection against significantly drifted influenza strains. In this study, we demonstrate that both monovalent and quadrivalent (Quad) formulations of M2SR are non-pathogenic in mouse and ferret models, eliciting robust neutralizing and non-neutralizing serum antibody responses to all strains within the formulation. Following challenge with wildtype influenza strains, vaccinated mice and ferrets demonstrated reduced weight loss, decreased viral replication in the upper and lower airways, and enhanced survival as compared to mock control groups. Mice vaccinated with H1N1 M2SR were completely protected from heterosubtypic H3N2 challenge, and BM2SR vaccines provided sterilizing immunity to mice challenged with a cross-lineage influenza B virus. Heterosubtypic cross-protection was also seen in the ferret model, with M2SR vaccinated animals exhibiting decreased viral titers in nasal washes and lungs following the challenge. BM2SR-vaccinated ferrets elicited robust neutralizing antibodies toward significantly drifted past and future influenza B strains. Mice and ferrets that received quadrivalent M2SR were able to mount immune responses equivalent to those seen with each of the four monovalent vaccines, demonstrating the absence of strain interference in the commercially relevant quadrivalent formulation. MDPI 2023-04-04 /pmc/articles/PMC10142185/ /pubmed/37112710 http://dx.doi.org/10.3390/vaccines11040798 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hill-Batorski, Lindsay Hatta, Yasuko Moser, Michael J. Sarawar, Sally Neumann, Gabriele Kawaoka, Yoshihiro Bilsel, Pamuk Quadrivalent Formulation of Intranasal Influenza Vaccine M2SR (M2-Deficient Single Replication) Protects against Drifted Influenza A and B Virus Challenge |
title | Quadrivalent Formulation of Intranasal Influenza Vaccine M2SR (M2-Deficient Single Replication) Protects against Drifted Influenza A and B Virus Challenge |
title_full | Quadrivalent Formulation of Intranasal Influenza Vaccine M2SR (M2-Deficient Single Replication) Protects against Drifted Influenza A and B Virus Challenge |
title_fullStr | Quadrivalent Formulation of Intranasal Influenza Vaccine M2SR (M2-Deficient Single Replication) Protects against Drifted Influenza A and B Virus Challenge |
title_full_unstemmed | Quadrivalent Formulation of Intranasal Influenza Vaccine M2SR (M2-Deficient Single Replication) Protects against Drifted Influenza A and B Virus Challenge |
title_short | Quadrivalent Formulation of Intranasal Influenza Vaccine M2SR (M2-Deficient Single Replication) Protects against Drifted Influenza A and B Virus Challenge |
title_sort | quadrivalent formulation of intranasal influenza vaccine m2sr (m2-deficient single replication) protects against drifted influenza a and b virus challenge |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142185/ https://www.ncbi.nlm.nih.gov/pubmed/37112710 http://dx.doi.org/10.3390/vaccines11040798 |
work_keys_str_mv | AT hillbatorskilindsay quadrivalentformulationofintranasalinfluenzavaccinem2srm2deficientsinglereplicationprotectsagainstdriftedinfluenzaaandbviruschallenge AT hattayasuko quadrivalentformulationofintranasalinfluenzavaccinem2srm2deficientsinglereplicationprotectsagainstdriftedinfluenzaaandbviruschallenge AT mosermichaelj quadrivalentformulationofintranasalinfluenzavaccinem2srm2deficientsinglereplicationprotectsagainstdriftedinfluenzaaandbviruschallenge AT sarawarsally quadrivalentformulationofintranasalinfluenzavaccinem2srm2deficientsinglereplicationprotectsagainstdriftedinfluenzaaandbviruschallenge AT neumanngabriele quadrivalentformulationofintranasalinfluenzavaccinem2srm2deficientsinglereplicationprotectsagainstdriftedinfluenzaaandbviruschallenge AT kawaokayoshihiro quadrivalentformulationofintranasalinfluenzavaccinem2srm2deficientsinglereplicationprotectsagainstdriftedinfluenzaaandbviruschallenge AT bilselpamuk quadrivalentformulationofintranasalinfluenzavaccinem2srm2deficientsinglereplicationprotectsagainstdriftedinfluenzaaandbviruschallenge |